Principal Financial Group Inc. Lowers Stake in ANI Pharmaceuticals, Inc. $ANIP

Principal Financial Group Inc. cut its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 34.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 98,489 shares of the specialty pharmaceutical company’s stock after selling 52,316 shares during the period. Principal Financial Group Inc. owned approximately 0.45% of ANI Pharmaceuticals worth $9,022,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ANIP. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the first quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd raised its stake in shares of ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 510 shares during the period. Newbridge Financial Services Group Inc. lifted its position in shares of ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 400 shares in the last quarter. State of Wyoming purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $50,000. Finally, CWM LLC grew its stake in ANI Pharmaceuticals by 159.1% in the 3rd quarter. CWM LLC now owns 798 shares of the specialty pharmaceutical company’s stock valued at $73,000 after acquiring an additional 490 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $76.70 on Friday. The company’s 50-day moving average price is $81.26 and its 200-day moving average price is $85.77. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The company has a market cap of $1.72 billion, a P/E ratio of 47.06 and a beta of 0.50. ANI Pharmaceuticals, Inc. has a twelve month low of $54.10 and a twelve month high of $99.50.

Insider Transactions at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the sale, the vice president directly owned 74,374 shares in the company, valued at $6,271,959.42. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Renee P. Tannenbaum sold 1,800 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the transaction, the director owned 25,157 shares in the company, valued at approximately $2,041,490.55. The trade was a 6.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,322 shares of company stock worth $354,816 in the last ninety days. Insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ANIP shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.